Keudell Morrison Wealth Management Takes Position in Astrazeneca Plc $AZN

Keudell Morrison Wealth Management purchased a new stake in Astrazeneca Plc (NYSE:AZN) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 4,789 shares of the company’s stock, valued at approximately $840,000.

Several other hedge funds have also modified their holdings of the business. Axxcess Wealth Management LLC increased its stake in Astrazeneca by 130.8% in the 4th quarter. Axxcess Wealth Management LLC now owns 54,302 shares of the company’s stock valued at $9,530,000 after purchasing an additional 30,772 shares in the last quarter. Texas Bank & Trust Co increased its stake in Astrazeneca by 4.6% in the 4th quarter. Texas Bank & Trust Co now owns 19,067 shares of the company’s stock valued at $3,346,000 after purchasing an additional 839 shares in the last quarter. Vestmark Advisory Solutions Inc. increased its stake in Astrazeneca by 135.5% in the 4th quarter. Vestmark Advisory Solutions Inc. now owns 161,954 shares of the company’s stock valued at $28,423,000 after purchasing an additional 93,186 shares in the last quarter. Addison Advisors LLC increased its stake in Astrazeneca by 3.9% in the 4th quarter. Addison Advisors LLC now owns 1,736 shares of the company’s stock valued at $305,000 after purchasing an additional 65 shares in the last quarter. Finally, FourThought Financial Partners LLC increased its stake in Astrazeneca by 2.7% in the 4th quarter. FourThought Financial Partners LLC now owns 150,996 shares of the company’s stock valued at $26,500,000 after purchasing an additional 3,986 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Astrazeneca Stock Performance

Astrazeneca stock opened at $189.88 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock has a fifty day moving average of $191.76 and a two-hundred day moving average of $182.72. The company has a market capitalization of $294.49 billion, a price-to-earnings ratio of 28.51, a PEG ratio of 1.54 and a beta of 0.26. Astrazeneca Plc has a fifty-two week low of $137.23 and a fifty-two week high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, analysts anticipate that Astrazeneca Plc will post 10.25 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on AZN shares. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Barclays raised Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. DZ Bank raised Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Finally, UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $205.33.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.